Literature Highlights

PsA Literature Highlights - July 2025

more…

Keywords:

Secukinumab, Uveitis, Safety, deucravacitinib, Efficacy, TYK2

IBD Literature Highlights - July 2025

more…

Keywords:

Efmarodocokin alfa, IL-22, Guselkumab, Tulisokibart, CD, UC

AxSpA Literature Highlights - July 2025

more…

Keywords:

Ixekizumab, malignancy, IL-17, safety, ASAS

RA Literature Highlights - July 2025

more…

Keywords:

Adalimumab, Baricitinib, Cardiovascular, Dosing, Efficacy, Filgotinib, JAK, Malignancy, MTX, Outcomes, Phase 2, Safety, Tofacitinib, Upadacitinib

IBD Literature Highlights - June 2025

more…

Keywords:

Efficacy, GI, JAK, LTE, Phase 2, Phase 3, Safety, Upadacitinib.

Psoriasis Literature Highlights – June 2025

more…

Keywords:

interleukin inhibitors, psoriasis, inflammatory bowel disease, meta-analysis, ixekizumab, risk difference, diarrhea, IL-17RA antagonist; non-interventional study; patient-reported outcomes (PROs); patient needs; patient benefits; quality of life; treatment goals, biologic therapy, deucravacitinib, hard-to-treat, psoriasis, PASI, treat-to-target threshold

RA Literature Highlights - June 2025

more…

Keywords:

Cardiovascular, Outcomes, Phase 3, Phase 4, JAK, LTE, Real-World, Safety, TNF, Tofacitinib, Upadacitinib.

PsA Literature Highlights - June 2025

more…

Keywords:

EULAR, GRAPPA, Outcomes, Pain, Real-world, Remission,

AxSpA Literature Highlights – June 2025

more…

Keywords:

Real-World, Remission

AxSpA Literature Highlights – May 2025

more…

Keywords:

Adalimumab, IBD, Imaging, Ixekizumab, JAK, Outcomes, Radiographic, Safety, Upadacitinib,